Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

3SBio Inc. (1530.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
5.810-0.080 (-1.36%)
As of 11:51AM HKT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.890
Open5.880
Bid5.800 x 0
Ask5.810 x 0
Day's Range5.700 - 5.920
52 Week Range5.700 - 12.300
Volume2,783,000
Avg. Volume8,565,117
Market Cap14.811B
Beta (5Y Monthly)0.95
PE Ratio (TTM)13.10
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 29, 2018
1y Target EstN/A
All
News
  • PR Newswire

    3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

    Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased investments in research and development, while significantly accelerating its pipeline. In the future, 3SBio will reinforce its position as an industry leader by enhancing its competitive edges with further integration of R&D, manufacturing, com

  • PR Newswire

    3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

    Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonstrated 3SBio's leading position in China's biopharmaceutical industry over the years, as well as the Company's strong growth momentum.

Advertisement
Advertisement